User Login  



Recent Disclosures of Clinical Candidates and SMR Award Lecture

1st December 2016
 NHLI, London

09.00 Registration and coffee
Session 1 - Chair: Dr Mike Hann, GSK
10.00 Welcome
10.05 2016 SMR Award Lecture & Presentation
Dr Francis Cuss, Bristol-Myers Squibb
‘The discovery, development and delivery of Opdivo’
The 2016 SMR Award winner is Opdivo® (nivolumab) – an anti-programmed death receptor-1 (PD-1) antibody approved to treat several cancers
10.50 Dr. Bernard Barlaam, AstraZeneca
'Identifying high quality, potent and selective inhibitors of ATM kinase for oncology therapies: Discovery of AZD0156’
11.30 Dr Thomas Fuchss, Merck KGaA
‘Highly potent and selective DNA-PK inhibitor M3814 with sustainable anti-tumour activity in combination with radiotherapy’
12.20 Lunch
13.20 SMR AGM (SMR members only)
Session 2 - Chair: Dr Pamela Williams, Astex Pharmaceuticals
13.40 Dr. David Edwards, Cancer Research UK
‘A different class of oncology therapeutic: development of MOv18 – a novel IgE-based therapeutic targeting folate receptor alpha’
14.20 Dr. Sandrine Vendeville, Tibotec J&J Belgium
‘Discovery of the clinical candidate JNJ-53718678, a potent and orally bioavailable fusion inhibitor of Respiratory Syncytial Virus’
15.00 Tea
Session 3 - Chair: Dr Richard Davenport, Takeda
15.30 Dr. John Liddle, GSK
‘Recent disclosure of a kynurenine 3-monooxygenase inhibitor as development candidate to treat severe acute pancreatitis - a drug discovery partnership between GSK and The University of Edinburgh'
16.20 Dr. Nick Clarke, Pfizer
‘Out with the old indication, bring in the new clinical compound for sickle cell disease’
17.00 Closing remarks and end of meeting

This meeting is sponsored by:




Back to Menu

  Register online now

   Home / Meetings / Membership / Student Bursaries / Administration /
   History of the SMR / SMR Award / Archive Material / Links / Contact Us
terms of use | smr 2018